MA52077A - Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole - Google Patents

Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole

Info

Publication number
MA52077A
MA52077A MA052077A MA52077A MA52077A MA 52077 A MA52077 A MA 52077A MA 052077 A MA052077 A MA 052077A MA 52077 A MA52077 A MA 52077A MA 52077 A MA52077 A MA 52077A
Authority
MA
Morocco
Prior art keywords
oxadiazole
channel inhibitors
potential channel
based transient
receiver potential
Prior art date
Application number
MA052077A
Other languages
English (en)
Inventor
Francis Beaumier
Huifen Chen
Lea Constantineau-Forget
Martin Déry
Chantal Grand-Maître
Robin Larouche-Gauthier
Luce Lépissier
Claudio Sturino
Jack Alexander Terrett
Elisia Villemure
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52077A publication Critical patent/MA52077A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Ink Jet (AREA)
  • Pyrrole Compounds (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
MA052077A 2018-03-19 2019-03-18 Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole MA52077A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862644987P 2018-03-19 2018-03-19
US201862676057P 2018-05-24 2018-05-24
US201862725488P 2018-08-31 2018-08-31
US201962812806P 2019-03-01 2019-03-01

Publications (1)

Publication Number Publication Date
MA52077A true MA52077A (fr) 2021-01-27

Family

ID=65952221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052077A MA52077A (fr) 2018-03-19 2019-03-18 Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole

Country Status (22)

Country Link
US (4) US10710994B2 (fr)
EP (1) EP3768260B1 (fr)
JP (2) JP7095106B2 (fr)
KR (2) KR102533094B1 (fr)
CN (1) CN111867585A (fr)
AU (1) AU2019237992B2 (fr)
BR (1) BR112020018983A2 (fr)
CA (1) CA3091486A1 (fr)
CL (1) CL2020002399A1 (fr)
CO (1) CO2020011852A2 (fr)
CR (1) CR20200413A (fr)
ES (1) ES3052569T3 (fr)
IL (2) IL276654B2 (fr)
MA (1) MA52077A (fr)
MX (1) MX2020009657A (fr)
MY (1) MY209839A (fr)
PE (1) PE20210660A1 (fr)
PH (1) PH12020551501A1 (fr)
SG (1) SG11202009136RA (fr)
TW (2) TWI829676B (fr)
UA (1) UA128787C2 (fr)
WO (1) WO2019182925A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51620B1 (fr) 2018-01-19 2024-10-31 Cytokinetics, Inc. Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
EP3814342B1 (fr) 2018-06-26 2022-07-27 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
EA202190657A1 (ru) 2018-08-31 2021-07-22 Сайтокинетикс, Инк. Ингибиторы саркомера сердца
AU2019331005B2 (en) 2018-08-31 2024-03-28 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
JP7688339B2 (ja) * 2020-01-22 2025-06-04 国立研究開発法人理化学研究所 新規化合物、およびその利用
WO2021233752A1 (fr) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Antagonistes de trpa1 pour le traitement de maladies associées à la douleur et à l'inflammation
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
CA3209557A1 (fr) 2021-03-04 2022-09-09 Bradley P. Morgan Inhibiteurs de sarcomes cardiaques
TW202309036A (zh) * 2021-04-14 2023-03-01 德商百靈佳殷格翰國際股份有限公司 -4,6-二酮衍生物
WO2022219015A1 (fr) * 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh Dérivés d'imidazo[4,5-d]pyridazinonyle utilisés en tant qu'inhibiteurs de trpa1
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
MX2024010316A (es) 2022-02-28 2024-08-30 Genentech Inc Procesos para la preparacion de compuestos de feniltetrahidrofurano.
CN118206482B (zh) * 2024-03-05 2025-04-25 山东京博生物科技有限公司 一种4-三氟甲基烟酰胺的合成方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
MXPA02010325A (es) * 2000-04-21 2003-04-25 Shionogi & Co Derivados de oxadiazol los cuales tienen efectos anticancer.
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (fr) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions et procedes de modulation du transport a travers la barriere hematho-encephalique
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2507762C (fr) 2002-12-03 2013-02-05 Blanchette Rockefeller Neurosciences Institute Porteurs artificiels a base de lipoproteines basse densite pour le transport de substances a travers la barriere hemato-encephalique
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
EP2142535A2 (fr) 2007-03-29 2010-01-13 Novartis Ag 3-imidazolyl-indoles pour le traitement de maladies prolifératives
US8163761B2 (en) 2007-06-22 2012-04-24 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US20120046305A1 (en) 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体
WO2010125469A1 (fr) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Composés hétérocycliques fusionnés à une pyrimidine dione en tant que modulateurs de trpa1
WO2011114184A1 (fr) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides de composés hétérocycliques à titre d'inhibiteurs de trpa1
WO2011132017A1 (fr) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Dérivés de pyrido[3,4-d]pyrimidinyl acétamide comme modulateurs de trpa1
EA023141B1 (ru) 2010-12-20 2016-04-29 Гленмарк Фармасьютикалс С.А. Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
WO2013108857A1 (fr) 2012-01-17 2013-07-25 味の素株式会社 Dérivé d'amine hétérocyclique et produit pharmaceutique le contenant
WO2014129796A1 (fr) 2013-02-20 2014-08-28 Lg Life Sciences Ltd. Agonistes des récepteurs de la sphingosine-1-phosphate, leurs procédés de préparation, et compositions pharmaceutiques les contenant en tant que principe actif
WO2015155306A1 (fr) 2014-04-11 2015-10-15 Almirall, S.A. Nouveaux antagonistes de trpa1
SG11201706451TA (en) 2015-02-15 2017-09-28 Hoffmann La Roche 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
WO2017060488A1 (fr) 2015-10-09 2017-04-13 Almirall, S.A. Nouveaux antagonistes de trpa1
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201831477A (zh) 2016-11-28 2018-09-01 瑞士商赫孚孟拉羅股份公司 噁二唑酮瞬時受體電位通道抑制劑
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors

Also Published As

Publication number Publication date
MX2020009657A (es) 2020-10-08
EP3768260C0 (fr) 2025-10-08
RU2020133430A (ru) 2022-04-19
PE20210660A1 (es) 2021-03-31
WO2019182925A1 (fr) 2019-09-26
KR102533094B1 (ko) 2023-05-16
CR20200413A (es) 2020-11-23
IL276654B1 (en) 2023-09-01
US20230121700A1 (en) 2023-04-20
UA128787C2 (uk) 2024-10-23
MY209839A (en) 2025-08-07
IL276654A (en) 2020-09-30
ES3052569T3 (en) 2026-01-12
JP7095106B2 (ja) 2022-07-04
TWI829676B (zh) 2024-01-21
TW202003510A (zh) 2020-01-16
CO2020011852A2 (es) 2020-10-20
AU2019237992A1 (en) 2020-09-03
CN111867585A (zh) 2020-10-30
IL304835A (en) 2023-09-01
TW202438496A (zh) 2024-10-01
KR20230070333A (ko) 2023-05-22
EP3768260A1 (fr) 2021-01-27
US20250122184A1 (en) 2025-04-17
BR112020018983A2 (pt) 2020-12-29
IL276654B2 (en) 2024-01-01
CL2020002399A1 (es) 2020-12-18
US12202824B2 (en) 2025-01-21
JP2022126779A (ja) 2022-08-30
US20190284179A1 (en) 2019-09-19
JP2021518388A (ja) 2021-08-02
AU2019237992B2 (en) 2025-01-30
KR20200133358A (ko) 2020-11-27
US20200308161A1 (en) 2020-10-01
PH12020551501A1 (en) 2021-09-06
EP3768260B1 (fr) 2025-10-08
US10710994B2 (en) 2020-07-14
SG11202009136RA (en) 2020-10-29
US11655245B2 (en) 2023-05-23
CA3091486A1 (fr) 2019-09-26

Similar Documents

Publication Publication Date Title
MA52077A (fr) Inhibiteurs de canal à potentiel de récepteur transitoire à base d'oxadiazole
DK3764956T3 (da) Fremgangsmåder til styring af resterende slitagetid for en stomianordning og tilhørende tilbehørsanordning
EP3830728A4 (fr) Remédiation d'attaques de recharge de vidage
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP4079000C0 (fr) Auto-localisation d'un dispositif audio
EP3884704A4 (fr) Procédure sans canal d'accès aléatoire (rach)
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
EP3892015A4 (fr) Rétroaction de sous-ensemble de base pour l'amélioration d'informations d'état de canal
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3747921A4 (fr) Composition de copolymère séquencé
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
EP3747433A4 (fr) Association d'immunothérapie cellulaire
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3735756A4 (fr) Indication de décalage de fréquence de porteuse non d'ancrage
EP3928587A4 (fr) Configuration d'occasion de canal d'accès aléatoire
EP3870179A4 (fr) Inhibition d'usp7
EP3825303A4 (fr) Inhibiteur du canal calcique de type t
EP3762456A4 (fr) Composition de dispersant d'asphaltène
IL286708A (en) Inhibitors of the n-terminal domain of the androgen receptor
MA53010A (fr) Formulations d'un inhibiteur de axl/mer
EP3648472A4 (fr) Récepteur mince
EP3695265A4 (fr) Amplificateur de tension destiné à une lentille d'électromouillage
EP3963995A4 (fr) Sélection de priorité d'accès à un canal
EP3786709C0 (fr) Caméra pour égouts